KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences Javascript is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results